The study is designed to establish the efficacy and tolerability of escitalopram in the
treatment of depressive episodes of mild to moderate severity in the elderly.
The study is designed as a mainly naturalistic study including all patients of 65 years of
age or above that judged by the clinician would benefit from treatment by an antidepressant
medication. The study is designed as a double-blind, randomised placebo controlled study with
two groups of active treatment (escitalopram in two doses, 5 or 10 mg daily) in a twelve week
period.
Phase:
Phase 4
Details
Lead Sponsor:
Psychiatric Hospital, Hillerod
Collaborators:
Amager Hospital Geriatric Department,Korsør, Vestsjælland Psychiatric Center Ballerup Psychogeriatric Unit, CU Hospital, Frederiksberg